Reuters logo
BRIEF-European commission approves Bristol-Myers Squibb’s opdivo (nivolumab)
June 2, 2017 / 9:22 PM / 6 months ago

BRIEF-European commission approves Bristol-Myers Squibb’s opdivo (nivolumab)

June 2 (Reuters) - Bristol-Myers Squibb Co:

* European Commission approves Bristol-Myers Squibb’s opdivo (nivolumab) for previously treated locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy

* Bristol-Myers Squibb Co - ‍opdivo is now approved in european union for eight indications in six distinct tumor types​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below